These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26991517)

  • 1. Therapeutic protein-drug interaction assessment for daclizumab high-yield process in patients with multiple sclerosis using a cocktail approach.
    Tran JQ; Othman AA; Wolstencroft P; Elkins J
    Br J Clin Pharmacol; 2016 Jul; 82(1):160-7. PubMed ID: 26991517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
    Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
    Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.
    Pai SM; Yamada H; Murata H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):667-682. PubMed ID: 37269147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
    Mohamed MF; Feng T; Enejosa JV; Fisniku O; Othman AA
    J Clin Pharmacol; 2020 Jan; 60(1):86-95. PubMed ID: 31378969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
    Khatri A; Cheng L; Camez A; Ignatenko S; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Jun; 58(6):805-814. PubMed ID: 30574672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
    Kim MG; Kim Y; Jeon JY; Kim DS
    Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
    Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
    Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
    Ermer J; Corcoran M; Martin P
    Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
    Zhuang Y; de Vries DE; Xu Z; Marciniak SJ; Chen D; Leon F; Davis HM; Zhou H
    J Clin Pharmacol; 2015 Dec; 55(12):1386-94. PubMed ID: 26054042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
    Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
    Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Potential Disease-Mediated Protein-Drug Interactions in Patients With Moderate-to-Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab.
    Zhu Y; Xu Y; Zhuang Y; Piantone A; Shu C; Chen D; Zhou H; Xu Z; Sharma A
    Clin Transl Sci; 2020 Nov; 13(6):1217-1226. PubMed ID: 32407591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
    Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
    Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
    Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
    Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
    Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
    Treijtel N; Collins C; van Bruijnsvoort M; Fuhr R; Ernault E; Gangaram-Panday S; Passier P
    Clin Pharmacol Drug Dev; 2019 May; 8(4):529-540. PubMed ID: 30730615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.